Giant congenital naevi are pigmented childhood lesions that frequently lead to melanoma, the most aggressive skin cancer. The mechanisms underlying this malignancy are largely unknown, and there are no effective therapies. Here we describe a mouse model for giant congenital naevi and show that naevi and melanoma prominently express Sox10, a transcription factor crucial for the formation of melanocytes from the neural crest. Strikingly, Sox10 haploinsufficiency counteracts Nras Q61K -driven congenital naevus and melanoma formation without affecting the physiological functions of neural crest derivatives in the skin. Moreover, Sox10 is also crucial for the maintenance of neoplastic cells in vivo. In human patients, virtually all congenital naevi and melanomas are SOX10 positive. Furthermore, SOX10 silencing in human melanoma cells suppresses neural crest stem cell properties, counteracts proliferation and cell survival, and completely abolishes in vivo tumour formation. Thus, SOX10 represents a promising target for the treatment of congenital naevi and melanoma in human patients.
at around 6 months of age 4 . In contrast, INK4a −/− mice barely develop melanoma 5 . Tyr::Nras Q61K expression is, therefore, the key event underlying melanoma formation in the Tyr::Nras Q61K 
INKa
−/− mouse model. Intriguingly, the morphological appearance and histological analysis of the skin of Tyr::Nras Q61K mice showed some challenging similarities to human giant congenital naevi, such as hyperpigmentation of the naevus nests close to the epidermis and the location of naevus cells around and within hair follicles and other adnexal structures, such as sebaceous glands (Fig. 1) . As in human patients, skin hyperpigmentation was apparent already at the first postnatal week in Tyr::Nras Q61K and Tyr::Nras Q61K INK4a −/− mice and was restricted to the dermis with virtually no epidermal involvement ( Fig. 1d-f ). Thus, Tyr::Nras Q61K INK4a −/− mice represent a model for melanoma arising from giant congenital naevi.
The transcription factor Sox10 is a key regulator of pigment cell formation during embryonic development and is expressed throughout all stages of melanocyte differentiation [6] [7] [8] [9] . To investigate whether Sox10 is also expressed in pathological lesions associated with the melanocytic lineage, we first performed an immunohistochemical analysis of human giant congenital naevi and revealed that SOX10 was highly expressed in all of the tested samples (n = 17; Table S1 ). Furthermore, extending studies by others [10] [11] [12] [13] [14] , we analysed the expression of SOX10 in a large set of human primary melanomas and melanoma metastases 15 . Most melanoma samples exhibited nuclear SOX10 staining (Fig. 2c,d ). Of note, 100% of all primary melanomas were marked by SOX10 expression, with more than 90% of all cells being SOX10 positive in 85% of all samples tested (n = 48). Of the metastatic samples, only 13% of the samples exhibited either very restricted or no nuclear SOX10 staining (n = 130; 2d ). In contrast, MITF, a transcription factor previously implicated in melanoma biology 16 , was not expressed in all primary melanoma samples and, in particular, was absent in 11% of tumour biopsies exhibiting dominant SOX10 expression ( Supplementary Fig. S1c,d ). Therefore, SOX10 might serve as a more sensitive marker for human giant congenital naevi and melanoma than other markers, including MITF, used at present.
In analogy to the human situation, dermal lesions reminiscent of giant congenital naevi exhibited broad Sox10 expression in Tyr::Nras Q61K and Tyr::Nras Q61K INK4a −/− mice from early postnatal stages onwards (Fig. 2e) . Moreover, Sox10 was prominently expressed in tumours generated in Tyr::Nras Q61K INK4a −/− mice at 6 months of age (Fig. 2f) . To address whether expression of Sox10 might be regulated by oncogenic Nras Q61K , we purified melanocytic cells from the skin of 1-month-old wild-type and Tyr::Nras Q61K mice by fluorescence-activated cell sorting (FACS), using the lineage markers MelanA and c-Kit for cell surface labelling ( Fig. 2g) . Quantitative real-time PCR analysis of the resulting cell fractions demonstrated that the level of Sox10 expression was significantly increased in melanoblasts from Tyr::Nras Q61K mice when compared with control melanoblasts, revealing Nras Q61K -mediated Sox10 activation (Fig. 2h) . The combined findings strongly suggest a central role for SOX10 in both giant congenital naevus and melanoma formation in humans and mice. During development, melanocytes arise from the neural crest, a transient embryonic structure containing multipotent neural crest stem cells (NCSCs). The absence of Sox10 affects NCSC survival and leads, therefore, to a loss of neural crest derivatives, including melanocytes 6, 7, 17 . In mice heterozygous for Sox10 null mutations, however, most neural crest derivatives are properly generated during development, although neural crest stem and progenitor cell maintenance, proliferation and fate decisions are impaired 6, 9, [18] [19] [20] [21] [22] . In particular, both in humans and mice, Sox10 haploinsufficiency is compatible with normal melanocyte specification and differentiation, but interferes with the generation of proper pigment cell numbers during development, leading to characteristic pigmentation defects at birth. In adults, however, physiological pigmentation is not affected by monoallelic Sox10 expression.
On the basis of this knowledge, we reasoned that Sox10 haploinsufficiency might possibly interfere with aberrant melanocytic cell production during the generation of giant naevi and melanoma without disturbing normal cell function. −/− mice (95±5 and 94±6%, respectively), Sox10 heterozygosity efficiently reverted this phenotype to an almost normal pigmentation pattern (hair follicles with ectopic pigmentation: 8 ± 2% and 9 ± 2%, respectively; Fig. 3c,d) . Likewise, the number of dermal cells positive for the melanocytic markers S100 or Dct (refs 23-25) was greatly reduced owing to Sox10 haploinsufficiency ( Fig. 3c and Supplementary Fig. S2c,d ). Samples were divided into four groups with expression in less than 10% of tumour cells (group I), from 10 to 50% (group II), from 50 to 90% (group III), and in more than 90% (group IV) of all tumour cells. The insets show high-magnification views; n = 178 melanomas. (e,f) Sox10 expression (red) was also detected in giant congenital naevi (mouse at postnatal day 9) and melanoma (6-month-old mouse) in the greying, however, revealing normal generation of melanocytes in these animals ( Supplementary Fig. S2a,b) .
To assess whether Sox10 haploinsufficiency not only influences congenital naevus formation, but also subsequent melanoma formation, Fig. S2b ). These findings demonstrate the efficient inhibition of melanoma formation by Sox10 haploinsufficiency in mice. During embryonic development, Sox10 regulates the balance between NCSC maintenance and multilineage differentiation 17, 26 . In particular, Sox10 haploinsufficiency counteracts maintenance and expansion of proliferative progenitor cells in different neural crest target structures 27, 28 . Therefore, to study the mechanisms underlying Sox10-dependent congenital naevus and melanoma formation, we addressed whether Sox10 haploinsufficiency affects cell proliferation by quantifying the number of Dct-positive cells expressing the proliferation marker Ki67 in wild-type, Tyr::Nras Q61K and Tyr::Nras Q61K Sox10 LacZ/+ mice ( Fig. 3g-j) . To this end, cell proliferation was assessed in melanocytic cells localized to hair follicles because this cellular compartment was present in all three genotypes. In the bulb area with differentiated melanocytes (Fig. 3h,j ) and in particular in the bulge area containing undifferentiated cells of the melanocyte lineage (Fig. 3g,i) , expression of Nras Q61K led to a highly significant increase in the number of proliferative Dct-positive cells. In Tyr::Nras Q61K Sox10 LacZ/+ mice, however, the level of proliferation was reduced almost to that of the control (Fig. 3g-j ). These experiments demonstrate that one of the main antagonistic effects of Sox10 haploinsufficiency on tumorigenesis is to counteract Nras Q61K -induced hyperproliferation.
To assess the importance of Sox10 functions for the maintenance of already established lesions, we used Tyr-CreERT2 mice to conditionally induce Sox10 heterozygosity in 2-month-old Tyr::Nras Q61K mice carrying a Sox10 fl allele 29 ( Fig. 4a,b) . To achieve inducible Credependent recombination and thus loss of Sox10 expression from the Sox10 fl allele, mice were injected with tamoxifen at 2 months of age, followed by their analysis at 12 months (Fig. 4a) . Intriguingly, hyperpigmentation was efficiently reverted in the back skin, snout and paws of these mice (Fig. 4b) . Moreover, histological analysis of skin sections showed that induced Sox10 haploinsufficiency resulted in an almost complete disappearance of ectopic dermal cells positive for pigment or Dct (Fig. 4c) . Indeed, whereas 96 ± 1% of all hair follicles were associated with ectopic Dct-positive cells in (Fig. 4d) . Thus, Sox10 is required not only for the formation but also for the maintenance of pre-melanoma lesions.
To address the relevance of these findings for human melanoma, we assessed whether in analogy to the mouse model, decreasing levels of SOX10 in human melanoma cell lines would interfere with melanoma maintenance. To this end, we performed RNA interference (RNAi)-mediated silencing of SOX10 in human melanoma cell lines 30 . In two distinct cell lines, SOX10 short hairpin RNA (shRNA) resulted in efficient downregulation of SOX10 expression, as revealed both by western blot analysis and immunocytochemistry ( Supplementary  Fig. S3 ). The capacity to form clones consisting of two or more cells was significantly reduced on SOX10 knockdown ( Fig. 4e ; clonogenicity of cells expressing control shRNA, 27 ± 2%; SOX10 shRNA, 4 ± 1%). To investigate in vivo tumour formation, immunocompromised mice were injected subcutaneously with melanoma cells expressing either SOX10 or control shRNA. After eight weeks, control cells consistently produced large, macroscopically evident tumours in vivo (11 out of 14 injections; Fig. 4f) . In striking contrast, none of the subcutaneous injections with SOX10 shRNA-expressing melanoma cells (0/16) led to tumour formation, even when the mice were kept for a further 6 weeks. These data demonstrate that silencing of SOX10 very effectively blocks tumorigenesis by human melanoma cells in vivo.
To address the mechanisms by which SOX10 controls human melanoma formation, we performed a comparative genome-wide transcriptome analysis of control versus SOX10 shRNA-expressing melanoma cells 48 and 96 h after RNAi-mediated silencing. Cluster analysis of transcriptionally regulated genes indicated that reducing SOX10 levels promotes apoptosis, cell cycle exit and mesectodermal differentiation ( Fig. 4g and Supplementary Fig. S4a ). These data were confirmed by measuring changes in the expression levels of 233 genes 48 and 96 h after SOX10 shRNA treatment, using quantitative real-time PCR (Fig. 4h,i and Supplementary Fig. S4b-f) . Several genes encoding apoptosis-control factors were dysregulated on silencing of SOX10 (Fig. 4h) . For instance, the anti-apoptotic factor BCL2 was significantly downregulated, whereas pro-apoptotic factors such as CASP1 and multiple TNF pathway components were highly upregulated in SOX10 knockdown cells. Moreover, RNAi-mediated silencing of SOX10 led to highly reduced expression levels of almost all genes tested that encode cyclins and cyclin-dependent kinases (CDKs), which trigger progression through the cell cycle ( Fig. 4i and Supplementary Fig. S4d ). Thus, in human melanoma cells, SOX10 controls multiple genes associated with cell survival and proliferation.
To functionally demonstrate the cell death-promoting effect of SOX10 silencing, we quantified the number of Annexin-V-positive cells using FACS analysis (Fig. 5a-c and Supplementary Fig. S5a-d) . This method revealed that in both human melanoma cell lines tested, the number of dying cells was significantly increased 48 and 96 h after SOX10 shRNA treatment of the cells (Fig. 5c) . Likewise, expression of SOX10 shRNA led to a more than ninefold increase in the percentage of apoptotic cells positive for activated caspase-3 ( Supplementary Fig.  S5c,d) . Together, these experiments revealed an important role for SOX10 in supporting the survival of melanoma cells. To address the function of SOX10 in cell cycle control, we analysed the cell cycle profile in control versus SOX10 shRNA-expressing human melanoma cells. These experiments demonstrated decreased cell cycle progression on SOX10 knockdown (Fig. 5d-h and Supplementary Fig. S5e-j) . Therefore, SOX10 is required for the maintenance of proliferative melanoma cells. Finally, as shown by immunocytological assays, loss of SOX10 promoted the formation of large, myofibroblast-like cells and expression of SOX9, which in neural crest development marks mesectodermal progenitor cells 28 ( Fig. 5i,l) . In addition, most SOX10 shRNA-expressing melanoma cells lost expression of the melanoma marker HMB45/MART-1 (Fig. 5j,m) . These findings are highly reminiscent of the effects seen on Sox10 loss of function in normal NCSCs, which include aberrant fate decisions, altered proliferation and survival, and increased differentiation into the mesectodermal lineages 17, 28 . Thus, SOX10 shRNA expression in human melanoma cells seems to interfere with NCSC properties. In support of this, SOX10 inactivation led to a marked reduction in the number of cells expressing the NCSC marker CD271 (p75 NTR ) (Fig. 5k,n) . Intriguingly, this marker has been associated before with cells implicated in melanoma initiation and propagation 10, 31 , which offers a plausible explanation for the anti-tumorigenic effect of SOX10 silencing.
In this study, we demonstrate intriguing similarities between the Tyr::Nras Q61K mouse model and human melanomas arising in giant congenital naevi. These naevi often carry Nras mutations and are associated with a dermal origin of the malignant melanocytic tumour cell population. Although melanoma formation in this model implicates the loss of tumour suppressor genes encoded by INK4a, the key event required for naevus formation and tumorigenesis is activation of Nras Q61K associated with expression of the transcription factor Sox10. Intriguingly, Sox10 haploinsufficiency fully prevents Nras Q61K -driven formation of premalignant lesions and tumours. In human melanoma cells, suppression of SOX10 counteracts melanoma formation by interfering with NCSC features and decreasing the number of CD271-positive tumour-initiating cells. On the basis of our data, SOX10 levels might represent a molecular target to suppress the formation of giant congenital naevi and their malignant transformation and to interfere with the expansion of established melanomas.
METHODS
Methods and any associated references are available in the online version of the paper. LacZ/+ and Sox10 fl / fl mice have been described previously 6, 29 . The Tyr-CreERT2 line 32 was provided by L. Chin (The University of Texas MD Anderson Cancer Center, Houston, Texas, USA). BALB/c nude, C3H and C57Bl/6 mice were obtained from Charles River. Mice were born with the expected ratio of Mendelian inheritance and no changes in gender ratios were observed. All animal experiments were performed in accordance with Swiss law and have been approved by the veterinary authorities of Zurich. The following secondary antibodies were used: anti-mouse, anti-rat, antigoat, anti-rabbit conjugated to Alexa-488, Alexa-546 or Cy3 secondary antibodies (dilution, 1:500, Invitrogen). Nuclei were stained with DAPI and slides were mounted with Fluorescent Mounting Medium (DAKO) to avoid bleaching. For bleaching of pigment, paraffin skin sections were deparaffinized, rehydrated and incubated in 10% H 2 O 2 overnight at room temperature. After the bleaching procedure, sections were incubated with primary antibodies as described above. Images were captured with a Leica DMI 6000B microscope and using LAS AF (Leica Application Suite Advanced Fluorescence) software.
Note: Supplementary Information is available in the online version of the paper

M E T H O D S
Tissue micorarrays. Paraffin-embedded tissue was used for the preparation of a primary melanoma and metastases tissue microarray. The representative region was taken with a core tissue biopsy (diameter, 0.6 mm; height, 3-4 mm). SOX10 immunohistochemistry was performed on paraffin sections of formalin-fixed tissues using the Ventana Benchmark automated staining system (Ventana Medical Systems). Primary monoclonal mouse antibody against SOX10 (mouse, dilution 1:100, clone 20B7, MAB2864, R&D) was used. Cell culture, proliferation and apoptosis assays. The A375 cell line was obtained from the ATCC collection. The A375 cell line carries a BRAF V600E mutation. M010817 and M070302 cell lines were described previously 10, 33 . The M010817 cell line has a NRAS Q61R mutation (BRAF not mutated). Cells were grown in RPMI-1640 medium supplemented with 10% FCS and 4 mM l-glutamine. The SOX10 shRNA sequence used was: 5 -GCCACGAGGTAATGTCCAA-3 (see also ref. 30 ). For short-term (48 and 96 h time points) cell culture assays, SOX10 shRNA and control plasmid delivery 30 into melanoma cells was achieved by electroporation using the Neon Transfection System (Invitrogen). For long-term SOX10 knockdown (in vivo subcutaneous injections for monitoring tumour formation capability), Sox10 shRNA and control lentiviral particles were obtained from Santa Cruz Biotechnology (catalogue numbers sc-38421-v and sc-108080). At day 1, melanoma cells were plated in 6-well plates and viral infection was performed 24 h later in the presence of 5 µg ml −1 Polybrene (sc-134220). After 48 h, medium was removed and replaced with fresh complete medium (without Polybrene) including puromycin (2 µg ml −1 ). For cell cycle analysis, the Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Invitrogen) was used. Cells were labelled with PI according to the manufacturer's protocol and the DNA content was measured using a BD FACSCanto II flow cytometer (BD Biosciences) and BD FACSDiva software (BD Biosciences). For measurement of apoptosis, the Annexin V : PE Apoptosis Detection Kit I (BD Pharmingen, 559763) was used.
Western blot. Electroporated cells were washed with ice-cold PBS and collected in lysis buffer containing protease inhibitors (cOmplete ULTRA protease inhibitor, catalogue number 05892970001, Roche). After 30 min of incubation on ice, cells were centrifuged at 15,700 rcf (relative centrifugal force) using a F45-24-11 rotor (Eppendorf) at 4 • C. SDS-PAGE was carried out with 20 µg of whole-cell protein lysate using precast Tris-HCl gels, 4-20% (catalogue number 161-1159, Bio Rad). The gels were blotted onto nitrocellulose membrane and blocked for 1 h in Odyssey blocking buffer (catalogue number 927-40000, LI-COR Biosciences). Anti-SOX10 antibodies (sc-17,342, Santa Cruz Biotechnology) were diluted 1:400 and applied overnight at 4 • C. After washing with PBST buffer (PBS with 0.1% Tween) several times, the membranes were incubated with secondary antibodies diluted 1:10,000 (IRDye 800CW donkey anti-goat IgG, catalogue number 926-32214, LI-COR). Blots were scanned on a LI-COR Odyssey imaging system. 
